GlassScriptPhysician profile
Reza N Mostofi
NPI 1972786895
$3,789.22
in general payments reported to CMS, 2019-2025
32 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,596 · 2020: $132 · 2023: $170 · 2024: $1,575 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,575 · Food and Beverage: $472 · Education: $13.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,575.00 |
| Food and Beverage | $472.46 |
| Education | $13.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,640.97 | 2019-2024 | |
| Pfizer INC. | $254.31 | 2019-2023 | |
| Genentech USA, INC. | $194.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $192.13 | 2019 | |
| Genmab U.S., INC. | $156.37 | 2023 | Epkinly |
| Sirtex Medical INC | $143.30 | 2025 | Sir-Spheres Microspheres |
| Incyte Corporation | $122.38 | 2019 | |
| Exelixis INC. | $93.29 | 2019 | |
| Abbvie INC. | $91.51 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $89.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $89.03 | 2019 | |
| Sobi, INC | $81.28 | 2025 | |
| Array Biopharma INC | $63.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $62.48 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $49.04 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $48.94 | 2019 | |
| Astellas Pharma US INC | $39.93 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.32 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.92 | 2019 | |
| Tersera Therapeutics LLC | $33.36 | 2019 | |
| Tesaro, INC. | $31.91 | 2019 | |
| Janssen Scientific Affairs, LLC | $29.29 | 2019 | |
| Amgen INC. | $27.60 | 2020 | |
| Gilead Sciences, INC. | $27.47 | 2019 | |
| Rigel Pharmaceuticals, INC. | $24.03 | 2019 | |
| Genzyme Corporation | $20.98 | 2020 | |
| Daiichi Sankyo INC. | $20.97 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $20.25 | 2019 | |
| Eisai INC. | $18.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $17.95 | 2019 | |
| Eusa Pharma (US) LLC | $14.17 | 2019 | |
| Secura Bio, INC. | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reza Mostofi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.